Concepedia

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

Alexander Drilon, Salvatore Siena, Rafał Dziadziuszko, Fabrice Barlési, Matthew Krebs, Alice T. Shaw, Filippo de Braud, Christian Rolfo, Myung‐Ju Ahn, Jürgen Wolf,

The Lancet Oncology · 2019 · 537 citations · 25 references

DOIFull text

Open access

Concepts

References

25

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel et al. · New England Journal of Medicine · 2018 · 6.6K citations · Full text

, , +16

Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer

Alice T. Shaw, Sai‐Hong Ignatius Ou, Yung‐Jue Bang et al. · New England Journal of Medicine · 2014 · 2K citations

, , +17

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

Robert C. Doebele, Alexander Drilon, Luis Paz‐Ares et al. · The Lancet Oncology · 2019 · 1.7K citations · Full text

, , +9

Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer

D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn et al. · New England Journal of Medicine · 2018 · 976 citations · Full text

, , +13

The landscape of kinase fusions in cancer

Nicolas Stransky, Ethan Cerami, Stefanie S. Schalm et al. · Nature Communications · 2014 · 969 citations · Full text

, , +17